 TORRANCE, Calif. , Aug. 17, 2021 PRNewswire -- Emmaus Life Sciences, Inc. OTC: EMMA, a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that on August 12, 2021, the National Health Regulatory Authority NHRA of the Kingdom of Bahrain approved a Temporary License for Importation of Pharmaceutical Product for Endari. 